Subject(s)

Cardiology/methods , Platelet Aggregation Inhibitors/therapeutic use , Platelet Aggregation/drug effects , Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors , Abciximab , Administration, Oral , Adult , Aged , Angina, Unstable/drug therapy , Angina, Unstable/therapy , Angioplasty, Balloon, Coronary , Antibodies, Monoclonal/adverse effects , Antibodies, Monoclonal/therapeutic use , Aspirin/pharmacology , Clinical Trials as Topic , Coronary Disease/blood , Coronary Disease/drug therapy , Coronary Disease/prevention & control , Coronary Disease/therapy , Double-Blind Method , Embolism/prevention & control , Eptifibatide , Female , Fibrinolytic Agents/adverse effects , Fibrinolytic Agents/therapeutic use , Follow-Up Studies , Forecasting , Hemorrhage/chemically induced , Humans , Immunoglobulin Fab Fragments/adverse effects , Immunoglobulin Fab Fragments/therapeutic use , Male , Meta-Analysis as Topic , Middle Aged , Multicenter Studies as Topic , Myocardial Infarction/drug therapy , Myocardial Infarction/therapy , Peptides/adverse effects , Peptides/therapeutic use , Platelet Aggregation Inhibitors/administration & dosage , Platelet Aggregation Inhibitors/adverse effects , Platelet Aggregation Inhibitors/pharmacology , Platelet Glycoprotein GPIIb-IIIa Complex/chemistry , Platelet Glycoprotein GPIIb-IIIa Complex/immunology , Prospective Studies , Risk , Stents , Structure-Activity Relationship , Tirofiban , Treatment Outcome , Tyrosine/adverse effects , Tyrosine/analogs & derivatives , Tyrosine/therapeutic use